Metastatic Triple-Negative Breast Cancer (mTNBC) Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Metastatic Triple-Negative Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Metastatic Triple-Negative Breast Cancer (mTNBC) pipeline landscape. It covers the Metastatic Triple-Negative Breast Cancer pipeline drug profiles, including Metastatic Triple-Negative Breast Cancer clinical trials and nonclinical stage products.

Key Takeaways from the Triple-Negative Breast Cancer Pipeline Report
• DelveInsight's Metastatic Triple-Negative Breast Cancer Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Metastatic Triple-Negative Breast Cancer.
• The leading Metastatic Triple-Negative Breast Cancer Companies include G1 Therapeutics, CytoDyn, Merck, Gilead Sciences, AstraZeneca, Hoffmann-La Roche, Celegene, and Others
• Promising Metastatic Triple-Negative Breast Cancer Pipeline Therapies include pembrolizumab, capecitabine, eribulin, Sacituzumab Govitecan-hziy, Paclitaxel, Atezolizumab, Ipatasertib, B013+Nab-Paclitaxel, Gemcitabine, and others
• May 2024:- Wake Forest University Health Sciences- A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC). The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer.
• May 2024:- Shanghai Jiaolian Drug Research and Development Co., Ltd-A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
• May 2024:- Amgen- A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases. The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.
• May 2024:- Gilead Sciences- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
• May 2024:- Kathy Miller- A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers. This is a randomized Phase II study of carboplatin monotherapy vs. carboplatin combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

To explore more information on the latest breakthroughs in the Metastatic Triple-Negative Breast Cancer treatment landscape of the report, click here @ Metastatic Triple-Negative Breast Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr


Metastatic Triple-Negative Breast Cancer Overview
Breast cancer (BC) is the most common malignant neoplasm in females. Approximately 10-20% of BCs do not express estrogen and progesterone receptors and lack amplification/overexpression of the human epidermal growth factor 2 receptor (HER2); therefore, they are known as triple-negative breast cancers (TNBCs) and constitute an aggressive histologic subtype. Overall prognosis for patients with mTNBC is worse than for the other BC subtypes, and more effective therapeutic options are needed.


Metastatic Triple-Negative Breast Cancer Emerging Drugs Profile

• Trilaciclib: G1 Therapeutics
Trilaciclib is a first-in-class FDA-designated "Breakthrough Therapy" designed to improve outcomes for people with cancer who are treated with chemotherapy. In June 2019, the company announced preliminary overall survival (OS) data from a randomized Phase 2 trial, which demonstrated that women with Metastatic Triple-Negative Breast Cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.

• Leronlimab (PRO 140): CytoDyn
Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

For further information, refer to the detailed Metastatic Triple-Negative Breast Cancer Unmet Needs, Metastatic Triple-Negative Breast Cancer Market Drivers, and Metastatic Triple-Negative Breast Cancer Market Barriers, click here for Metastatic Triple-Negative Breast Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Triple-Negative Breast Cancer Therapeutics Assessment
There are approx. 4+ key companies which are developing the therapies for Metastatic Triple-Negative Breast Cancer (mTNBC). The companies which have their Metastatic Triple-Negative Breast Cancer (mTNBC) drug candidates in the most advanced stage, i.e. phase II include, G1 Therapeutics.

DelveInsight's Metastatic Triple-Negative Breast Cancer Pipeline Report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Request a sample and discover the recent advances in Metastatic Triple-Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Triple-Negative Breast Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Triple-Negative Breast Cancer Companies
G1 Therapeutics, CytoDyn, Merck, Gilead Sciences, AstraZeneca, Hoffmann-La Roche, Celegene, and Others.

Metastatic Triple-Negative Breast Cancer (mTNBC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Metastatic Triple-Negative Breast Cancer Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Dive deep into rich insights for drugs for Metastatic Triple-Negative Breast Cancer Pipeline, click here @ Metastatic Triple-Negative Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Triple-Negative Breast Cancer Pipeline Report
• Coverage- Global
• Metastatic Triple-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Triple-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Triple-Negative Breast Cancer Companies- G1 Therapeutics, CytoDyn, Merck, Gilead Sciences, AstraZeneca, Hoffmann-La Roche, Celegene, and Others.
• Metastatic Triple-Negative Breast Cancer Therapies- pembrolizumab, capecitabine, eribulin, Sacituzumab Govitecan-hziy, Paclitaxel, Atezolizumab, Ipatasertib, B013+Nab-Paclitaxel, Gemcitabine, and others

Got Queries? Find out the related information on Metastatic Triple-Negative Breast Cancer Mergers and acquisitions, Metastatic Triple-Negative Breast Cancer Licensing Activities @ Metastatic Triple-Negative Breast Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Metastatic Triple-Negative Breast Cancer (mTNBC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Triple-Negative Breast Cancer (mTNBC)- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Metastatic Triple-Negative Breast Cancer (mTNBC) Collaboration Deals
9. Mid Stage Products (Phase II)
10. Trilaciclib: G1 Therapeutics
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug name: Company name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Metastatic Triple-Negative Breast Cancer (mTNBC) Key Companies
17. Metastatic Triple-Negative Breast Cancer (mTNBC) Key Products
18. Metastatic Triple-Negative Breast Cancer (mTNBC)- Unmet Needs
19. Metastatic Triple-Negative Breast Cancer (mTNBC)- Market Drivers and Barriers
20. Metastatic Triple-Negative Breast Cancer (mTNBC)- Future Perspectives and Conclusion
21. Metastatic Triple-Negative Breast Cancer (mTNBC) Analyst Views
22. Metastatic Triple-Negative Breast Cancer (mTNBC) Key Companies
23. Appendix

List of Important Links-

https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.